NASDAQ:FTH Sensei Biotherapeutics (FTH) Stock Price, News & Analysis $27.66 +0.57 (+2.08%) As of 11:14 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Sensei Biotherapeutics Stock (NASDAQ:FTH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sensei Biotherapeutics alerts:Sign Up Key Stats Today's Range$26.00▼$27.4750-Day Range$24.39▼$40.0552-Week Range$7.45▼$42.14Volume49,174 shsAverage Volume238,757 shsMarket Capitalization$714.86 millionP/E RatioN/ADividend YieldN/APrice Target$56.25Consensus RatingModerate Buy Company Overview Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing cancer immunotherapies designed to activate the immune system against tumors. The company’s approach is intended to address immune suppression within the tumor microenvironment and potentially improve patients’ responses to existing cancer treatments. Sensei’s pipeline has included antibody-based and vaccine-based immunotherapies. Its lead programs have included SNS-101, an antibody designed to target the VISTA immune checkpoint, and earlier ImmunoPhage-based programs intended to stimulate tumor-specific immune responses. These candidates have been evaluated in clinical development for solid tumors, either as standalone treatments or in combination with other immunotherapies. Sensei Biotherapeutics is headquartered in the United States and has focused its research and clinical-development activities on oncology applications. The company’s publicly reported Nasdaq ticker has been SNSE; FTH does not appear to correspond to Sensei Biotherapeutics. Leadership and pipeline status may change as the company advances or reprioritizes its development programs.AI Generated. May Contain Errors. Read More Sensei Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreFTH MarketRank™: Sensei Biotherapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 376th out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingSensei Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 2 strong buy ratings, 11 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialSensei Biotherapeutics has a consensus price target of $56.25, representing about 107.6% upside from its current price of $27.10.Amount of Analyst CoverageSensei Biotherapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sensei Biotherapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sensei Biotherapeutics are expected to grow in the coming year, from ($13.69) to ($3.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sensei Biotherapeutics is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sensei Biotherapeutics is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSensei Biotherapeutics has a P/B Ratio of 1.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.49% of the float of Sensei Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverSensei Biotherapeutics has a short interest ratio ("days to cover") of 4.37.Change versus previous monthShort interest in Sensei Biotherapeutics has recently increased by 20.08%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSensei Biotherapeutics does not currently pay a dividend.Dividend GrowthSensei Biotherapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.59 News SentimentSensei Biotherapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Sensei Biotherapeutics this week, compared to 3 articles on an average week.Search Interest8 people have searched for FTH on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Sensei Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sensei Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders7.00% of the stock of Sensei Biotherapeutics is held by insiders.Percentage Held by Institutions10.50% of the stock of Sensei Biotherapeutics is held by institutions.Read more about Sensei Biotherapeutics' insider trading history. Receive FTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sensei Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FTH Stock News HeadlinesSensei Biotherapeutics (NASDAQ:FTH) Shares Up 5.6% - Here's What HappenedOctober 2, 2026 | americanbankingnews.comWall Street Zen Downgrades Sensei Biotherapeutics (NASDAQ:FTH) to SellSeptember 26, 2026 | americanbankingnews.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.October 6 at 1:00 AM | Behind the Markets (Ad)Faeth Therapeutics: 'Buy' PIKTOR EC Data Year-End 2026 And HR+/HER2- BC Drug ExpansionSeptember 18, 2026 | seekingalpha.comFaeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of DirectorsSeptember 17, 2026 | businesswire.comTD Cowen Initiates Coverage on Faeth Therapeutics With Buy RatingSeptember 9, 2026 | marketscreener.comMFaeth Therapeutics to Participate in Upcoming September Investor ConferencesSeptember 1, 2026 | businesswire.comFaeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial CancerAugust 17, 2026 | businesswire.comSee More Headlines FTH Stock Analysis - Frequently Asked Questions How have FTH shares performed this year? Sensei Biotherapeutics' stock was trading at $16.65 on June 17, 2026. Since then, FTH shares have increased by 62.8% and is now trading at $27.10. How were Sensei Biotherapeutics' earnings last quarter? Sensei Biotherapeutics, Inc. (NASDAQ:FTH) posted its earnings results on Tuesday, August, 4th. The company reported ($2.84) EPS for the quarter, topping analysts' consensus estimates of ($5.05) by $2.21. When did Sensei Biotherapeutics' stock split? Sensei Biotherapeutics shares reverse split on the morning of Tuesday, June 17th 2025.The 1-20 reverse split was announced on Friday, June 13th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 16th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Sensei Biotherapeutics? Shares of FTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sensei Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sensei Biotherapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Tesla (TSLA), Advanced Micro Devices (AMD), Plug Power (PLUG), PayPal (PYPL) and Walt Disney (DIS). Company Calendar Last Earnings8/04/2026Today10/06/2026KOL event10/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 FTH's financial health is in the Green zone, according to TradeSmith. FTH has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:FTH Previous SymbolNASDAQ:SNSE CIK1829802 Webwww.faeththerapeutics.com Phone(512) 200-2982FaxN/AEmployees29Year Founded1999Price Target and Rating Average Price Target for Sensei Biotherapeutics$56.25 High Price Target$70.00 Low Price Target$50.00 Potential Upside/Downside+114.6%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($141.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.08 million Net MarginsN/A Pretax MarginN/A Return on Equity-1,012.17% Return on Assets-175.69% Debt Debt-to-Equity RatioN/A Current Ratio19.69 Quick Ratio19.69 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$14.74 per share Price / Book1.78Miscellaneous Outstanding Shares25,840,000Free Float24,031,000Market Cap$677.40 million OptionableNot Optionable Beta-0.29 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:FTH) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredThe case for $20,000 gold before year endPresident Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and A...Stansberry Research | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredAnthropic’s $40 million midterm moveAnthropic, creator of Claude, has committed $40 million to Public First Action, a nonpartisan group advocating...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sensei Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sensei Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FTH Stock Alerts